Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW Authors: Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Barnaby Hunt, Samuel J. P. Malkin, Barrie Chubb, Tina Damgaard, Rikke Borg Published: 2025 ABSTRACT BackgroundThe FLOW clinical trial recently demonstrated that the glucagon-like peptide-1 receptor agonist once-weekly semaglutide 1 mg was associated with kidney- and cardio-protective effects (the latter already shown in the SUSTAIN 6 trial) compared with placebo, both in addition to standard of care (SoC), in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). This study assessed the long-term cost-effectiveness of semaglutide versus placebo in people with T2D and CKD in Denmark, based on outcomes from FLOW.MethodsLife expectancy, quality-adjusted life expectancy, cumulative incidence of diabetes-related complications, and costs were projected over a lifetime time horizon using the PRIME T2D Model. Baseline cohort characteristics and changes in risk factors with semaglutide and placebo were taken from FLOW, with extrapolation over patient lifetimes. Outcomes were assessed for the full population and subgroups receiving/not receiving sodium-glucose cotransporter-2 (SGLT-2) inhibitors at baseline. Quality-of-life disutilities and Denmark-specific costs (expressed in 2023 Danish Kroner [DKK]) were applied to capture the impact of diabetes-related complications and pharmacy costs.ResultsTreatment with semaglutide was projected to improve long-term quality-adjusted life expectancy by 0.60 quality-adjusted life years (QALYs) compared with placebo in the full population and by 0.44 and 0.62 QALYs in subgroups receiving/not receiving SGLT-2 inhibitors at baseline, respectively. Differences were predominantly driven by a reduced incidence of kidney failure with semaglutide versus placebo. Semaglutide was associated with long-term, per-person cost savings of DKK 6,068 in the full population and DKK 9,212 in those not receiving SGLT-2 inhibitors at baseline, leading to semaglutide being a dominant treatment compared with placebo. In patients receiving SGLT-2 inhibitors at baseline, semaglutide was cost-effective with an ICER of DKK 19,167 per QALY gained.ConclusionsAdding semaglutide to SoC was projected to be highly cost‐effective over the long term in people with T2D and CKD in a Danish healthcare setting, based on patient characteristics and treatment effects from FLOW. Trial registration NCT03819153, first submitted on January 18, 2019.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12933-025-03002-1. Research insights What is currently known about this topic? The kidney- and cardio-protective effects of semaglutide were shown in people with T2D and CKD in FLOW. The kidney- and cardio-protective effects of semaglutide were shown in people with T2D and CKD in FLOW. The kidney- and cardio-protective effects of semaglutide were shown in people with T2D and CKD in FLOW. Projection with a validated model is needed to assess long-term cost-effectiveness of T2D drugs. Projection with a validated model is needed to assess long-term cost-effectiveness of T2D drugs. Projection with a validated model is needed to assess long-term cost-effectiveness of T2D drugs. What is the key research question? Is semaglutide a cost-effective treatment versus placebo for people with T2D and CKD in Denmark? Is semaglutide a cost-effective treatment versus placebo for people with T2D and CKD in Denmark? Is semaglutide a cost-effective treatment versus placebo for people with T2D and CKD in Denmark? What is new? Semaglutide improves quality-adjusted life expectancy and reduces costs versus placebo in people with T2D and CKD in Denmark. Semaglutide improves quality-adjusted life expectancy and reduces costs versus placebo in people with T2D and CKD in Denmark. Semaglutide improves quality-adjusted life expectancy and reduces costs versus placebo in people with T2D and CKD in Denmark. Lower incidence of kidney failure with semaglutide was a key driver of improved long-term outcomes. Lower incidence of kidney failure with semaglutide was a key driver of improved long-term outcomes. Lower incidence of kidney failure with semaglutide was a key driver of improved long-term outcomes. How might this study influence clinical practice? Semaglutide 1 mg is a potential treatment option for people with T2D and CKD. Semaglutide 1 mg is a potential treatment option for people with T2D and CKD. Semaglutide 1 mg is a potential treatment option for people with T2D and CKD. Cost-effectiveness results should be considered by healthcare payers and prescribing physicians. Cost-effectiveness results should be considered by healthcare payers and prescribing physicians. Cost-effectiveness results should be considered by healthcare payers and prescribing physicians. Introduction Diabetes is a chronic disease that affected 589 million (11%) of adults globally in 2025, with over 90% of cases attributed to type 2 diabetes (T2D) [1]. In Denmark, estimates suggest that the number of people with T2D increased from 260,000 to 325,000 between 2018 and 2023, and this is expected to rise to 420,000 by 2030 [2]. The total incremental healthcare cost of an individual with newly diagnosed T2D in Denmark is estimated to be approximately Danish Kroner (DKK) 10,000 per year, with costs increasing as patients experience diabetes-related complications [3–5]. Diabetes is one of the leading causes of chronic kidney disease (CKD), with 30–40% of people with diabetes developing CKD [6]. In the Danish setting, an observational study conducted at primary care clinics found that 32% of people with CKD had diabetes [7]. The number of cases of CKD caused by T2D increased by approximately 74% between 1990 and 2017 worldwide [8]. CKD markedly amplifies the risk of cardiovascular disease, cardiovascular death, and all-cause mortality among people with diabetes, leading to substantial increases in the clinical and economic burden associated with T2D [9, 10]. Optimizing treatment to improve outcomes in people with T2D and CKD represents an unmet need in the Danish healthcare system. For almost 30 years, renin–angiotensin–aldosterone system (RAAS) inhibition has been the cornerstone of treatment for CKD, but recently a range of treatments have been developed to prevent and delay the progression of CKD in people with diabetes [11]. These treatments are recommended in international and Danish guidelines and include: sodium-glucose cotransporter-2 (SGLT-2) inhibitors (recommended in people with T2D and CKD), glucagon-like peptide (GLP-1) receptor agonists (recommended for improving glycemic control in older guidelines and for slowing CKD progression in newer guidelines), or non-steroidal mineralocorticoid receptor antagonists (ns-MRAs [finerenone], recommended for people with T2D, normal serum potassium concentration, and urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g despite RAAS inhibition) [12–15]. In Denmark, the use of GLP-1 receptor agonists in people with T2D has increased markedly, from 9% in 2015 to 31% in 2024 [16]. The efficacy and safety of the GLP-1 receptor agonist semaglutide 1 mg as a glucose-lowering medication was demonstrated in the SUSTAIN trial program [17–21]. The phase 3b FLOW clinical trial was the first specifically designed to evaluate the impact of a GLP-1 receptor agonist on kidney outcomes in people with T2D and CKD [22, 23]. The study compared the efficacy and safety of once-weekly subcutaneous semaglutide 1 mg versus placebo, both in addition to standard of care (SoC), including a maximally tolerated dose of RAAS inhibitors. The study enrolled patients across the Kidney Disease: Improving Global Outcomes (KDIGO) stages, with 1%, 20%, 30%, 38% and 11% of study participants in stages 1, 2, 3a, 3b, 4 and 5, respectively. The primary outcome was major kidney disease events, a composite of the onset of kidney failure (dialysis, transplantation, or an estimated glomerular filtration rate [eGFR] of < 15 mL/min/1.73 m2), at least a 50% reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. The risk of the primary outcome was reduced by 24% in the semaglutide group compared with the placebo group (P = 0.0003), corresponding to number needed to treat (NNT) of 20 at 3 years [22]. As part of the FLOW clinical trial, a prespecified analysis investigated outcomes stratified by baseline use of SGLT-2 inhibitors [24]. Of the 3,533 participants, a total of 550 individuals (15.6%) reported SGLT-2 inhibitor use at baseline. In the subgroup of patients not receiving SGLT-2 inhibitors at baseline, semaglutide was associated with a statistically significant reduction in risk of the primary endpoint of 27% (hazard ratio 0.73, 95% confidence interval 0.63–0.85). No statistically significant difference in the primary outcome was observed in the subgroup of patients receiving SGLT-2 inhibitors at baseline (hazard ratio 1.07, 95% confidence interval 0.69–1.67). In the full FLOW population and the subgroups receiving and not receiving SGLT-2 inhibitors at baseline, statistically significant differences were observed in glycated hemoglobin (HbA1c) and body mass index (BMI) changes in the first 3 years, in urine albumin‐to-creatinine ratio (UACR) reduction during the first 2 years (by 32%, 24% and 34%, respectively), as well as in the first-year change in eGFR [23, 24]. As SGLT-2 inhibitor use is now standard of care in people with CKD and T2D, exploring outcomes in patients receiving and not receiving SGLT-2 inhibitors is of particular interest. The present study aimed to project long-term outcomes, including life expectancy, quality-adjusted life expectancy and direct costs, to assess the cost-effectiveness of semaglutide 1 mg versus placebo (both in addition to SoC) in people with T2D and CKD, based on data from the full FLOW population as well as the subgroups receiving and not receiving SGLT-2 inhibitors at baseline. Methods Modeling approach Clinical and cost outcomes were projected over patient lifetimes using the PRIME T2D Model. The model is product-independent and has been internally and externally validated against numerous diabetes trials, including recent cardiovascular outcomes trials (CVOTs) [25]. The model uses patient-level simulation to capture disease complexity and brings novel approaches to long-standing modeling challenges in T2D, including use of model averaging to estimate the risk of specific complications (where the average of multiple risk equations derived from different populations is applied, with higher weight given to equations derived in populations that more closely match the characteristics of each sampled patient) and modeling the progression of CKD based on mapping of eGFR to KDIGO stages 1–5, with kidney failure defined as KDIGO stage 5. The risk of complications is modeled based on the progression of risk factors (e.g., HbA1c, BMI, systolic blood pressure [SBP]), using specific risk equations derived from published studies identified through a systematic literature review conducted as part of the PRIME T2D Model development. The model captures mortality related to diabetes-related complications (based on UKPDS Outcomes Model 2 [UKPDS OM2] data) and background mortality based on country-specific, cause-subtracted life tables published by the World Health Organization. [26, 27] Model outputs include life expectancy (measured in years), quality-adjusted life expectancy (measured in quality-adjusted life years [QALYs]), cumulative incidence of all modeled T2D-related complications and costs. Differences in quality-adjusted life expectancy and costs between simulation arms are used to calculate incremental cost-effectiveness ratios (ICERs). The analysis used a time horizon of 60 years to capture all patient mortality. In addition, outcomes were assessed at years 3 and 4 of the simulation in a supporting analysis, aligning with the 3.4-year median follow-up of FLOW as closely as possible, given that the model uses an annual cycle length. Annual discount rates of 3.0% were applied for clinical and cost outcomes, in line with the mid-point between discount rates recommended for different time horizons in the “Guide to socio-economic impact assessments” published by the Danish Ministry of Finance [28]. Baseline characteristics and treatment effects Baseline cohort characteristics were taken from the FLOW clinical trial for the full FLOW population, as well as for the two subgroups of patients receiving and not receiving SGLT-2 inhibitors at baseline (Supplementary Material, Table S1) [22–24]. The analysis captured changes in risk factors with semaglutide 1 mg and placebo, including HbA1c, SBP, BMI, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, eGFR, and hemoglobin, as well as severe hypoglycemic event rates, with data taken from the FLOW clinical trial for the first 3 years of the analysis [23, 24]. A description of changes in risk factors and the statistical significance of differences between the two trial arms is provided in the Supplementary Material, Table S2. Long-term parameter progression Beyond the trial duration, patients were assumed to continue semaglutide treatment as an add-on to SoC for the remainder of their lifetimes. This assumption was considered appropriate as patients had advanced diabetes (mean duration of 17.4 years), received semaglutide late in the treatment pathway (with 61.4% of patients in FLOW already receiving insulin), and use of semaglutide aimed not only to treat T2D but also to slow CKD progression. After application of treatment effects in the first 3 years of the analysis, HbA1c, SBP, BMI, HDL and LDL cholesterol, and hemoglobin were assumed to remain constant. This is supported by several recent medium-term and long-term diabetes studies that have shown that physiological parameters remain relatively constant when receiving modern diabetes therapies, with this stability also observed in FLOW [20, 21, 29–35]. eGFR was assumed to continue to decline at a constant annual rate, based on the eGFR chronic slope reported in FLOW, until patients reached KDIGO stage 5. The impacts of alternative durations of treatment and physiological parameter progressions were assessed in sensitivity analyses. Cost data All costs were accounted from Danish healthcare payer perspective and expressed in 2023 Danish kroner (DKK), inflated where necessary using the Harmonised Indices of Consumer Prices (HICP) in Denmark published by Eurostat [36]. Costs of treating diabetes-related complications were based on previously published studies (Supplementary Material, Table S3) [37–41]. Treatment costs included costs of interventions, concomitant medications used at baseline and initiated during the trial period, and consumables. Pharmacy costs were matched to prices paid by pharmacists in Denmark. Concomitant medications used in FLOW (including insulin [short-acting, intermediate-acting, long-acting, and premixed], metformin, sulfonylureas, and dipeptidyl peptidase-4 [DPP-4] and SGLT-2 inhibitors) were matched to the most commonly used medication in each class in Denmark. Use of concomitant medications at baseline and rates of initiation were taken from the FLOW trial and were used in the calculation of the annual treatment costs to reflect the cost of SoC. Beyond the trial duration, use of concomitant medications was conservatively assumed to be equal in both treatment arms. The number of required needles per day was calculated based on the use of insulin, assuming one needle per day for long-acting, intermediate-acting and premixed insulin, and three needles per day for short-acting insulin. Utility data A systematic review performed during the development of the PRIME T2D Model was used to inform health-state utilities and event-based disutilities applied in the analyses (Supplementary Material, Table S4) [42–48]. In addition to the impact of diabetes-related complications on quality of life, the impact of changes in weight was captured by applying a disutility of − 0.0061 per BMI unit above 25 kg/m.2.[45] Key drivers of clinical outcomes The impact of changes in each individual risk factor on the overall improvement in quality-adjusted life expectancy with semaglutide versus placebo in the full FLOW population was evaluated by applying each of these changes in turn. A series of five simulations were prepared in which only the treatment effect of one of HbA1c, SBP, BMI, serum lipids, or eGFR was applied sequentially in the semaglutide arm, with all other parameters equal to the values in the comparator arm. The difference in quality-adjusted life expectancy across treatment arms resulting from each simulation was compared with the total improvement in quality-adjusted life expectancy in the base case analysis and expressed as a percentage. Sensitivity analyses The projection of long-term outcomes is associated with uncertainty. Therefore, sensitivity analyses were performed around key parameters and assumptions in the modeling analysis to assess the robustness of the base case findings in the full FLOW population. The impact of assessing outcomes over shorter time horizons was evaluated by running analyses over 10 and 20 years. Based on guideline published by the Danish Ministry of Finance, analyses were performed with annual discount rates of 0%, 2.5% and 3.5% [28]. An additional analysis was performed with only treatment effects in the semaglutide arm that were statistically significantly different from the treatment effects in the placebo arm applied (with other effects matched to the placebo arm). Discontinuation of semaglutide was captured in a series of analyses. Patients were assumed to discontinue semaglutide after 3 or 5 years (in separate analyses) to match previous long-term cost-effectiveness analyses of GLP-1 receptor agonists submitted to the National Institute for Health and Care Excellence (NICE) and published in peer-reviewed journals [49–52]. For both of these analyses, two risk factors progression approaches were investigated: (1) all risk factors were brought to the level in the comparator arm after discontinuation, (2) all risk factors were brought to their level in the comparator arm after discontinuation except for eGFR, which was assumed to decline at the same rate as with placebo (parallel slope). The impact of alternative risk of complications methodology was assessed across a range of analyses. In the base case analysis, eGFR continued to decline beyond the trial duration based on the chronic slope observed in each treatment arm of FLOW, and an analysis was performed with the progression of eGFR beyond the trial period based on the equation described in Zoppini et al. (the default approach in the PRIME T2D Model in absence of other data) [53]. In a further analysis, renal disease was modeled via the UKPDS OM2 risk equation rather than mapping eGFR to KDIGO stages 1–5 as in the base case [26]. The model averaging approach for cardiovascular disease used in the base case analysis was replaced by use of the BRAVO risk equations [44]. To reflect the increased risk of cardiovascular disease in people with CKD, an analysis was performed with a hazard ratio of 1.41 applied to the risk of cardiovascular disease calculated by the PRIME T2D Model in both arms, based on data from ACCORD [54]. In addition, variations were applied in the cost of complications and treatment costs. Analyses were performed with the costs of treating diabetes-related complications increased and decreased by 20%. The importance of the kidney failure treatment method was assessed by assuming that all patients with kidney failure received a renal transplant, rather than dialysis as applied in the base case analysis. Analyses were performed with no difference in concomitant medication use between the treatment arms (matched to the semaglutide arm), and with end-of-trial concomitant medication use continued for the remainder of patient lifetimes. The impact of using alternative BMI disutilities was assessed by applying a value of − 0.01 per BMI unit above 25 kg/m2 from Lee et al., and by removing the BMI disutility entirely from the analysis [55]. A probabilistic sensitivity analysis was performed with variation in all modeled parameters simultaneously. Subgroup analyses Subgroup analyses were performed assessing outcomes in patients receiving and not receiving SGLT-2 inhibitors at baseline (based on the publication by Mann et al.), with baseline characteristics reported in the Supplementary Material (Table S1) [24]. All approaches and assumptions were equivalent to the long-term analysis based on the full FLOW population, with the same sensitivity analyses performed in all populations. No cost-effectiveness analysis has been conducted specifically for people who initiated SGLT-2 inhibitors during the trial, as stratifying subgroups by medications started during the trial would violate randomization. Such an approach could create imbalanced subgroups and introduce confounding, resulting in non-robust findings. However, initiation of SGLT-2 inhibitors during the trial was accounted for in the cost of concomitant medications in the full FLOW population and the subgroup of patients not receiving SGLT-2 inhibitors at baseline (and, arguably, in the corresponding clinical data, with outcomes from these trial populations reflective of the proportions of patients initiating these medications). Results Base case analysis Over the first 3–4 years of the analysis (matching the FLOW median follow-up of 3.4 years), treatment with semaglutide 1 mg increased life expectancy by 0.05 and 0.07 years at years 3 and 4, respectively, and improved quality-adjusted life expectancy by 0.05 and 0.07 QALYs at years 3 and 4, respectively, compared with placebo. Clinical benefits of semaglutide were accompanied by cost savings of DKK 4,347 and DKK 8,124 per person after 3 and 4 years, respectively. With short-term projections of improved quality-adjusted life expectancy and reduced costs, semaglutide could be considered a dominant treatment in people with T2D and CKD compared with placebo based on the full FLOW population data, even over short time horizons. The comparison of projected and actual kidney failure cumulative incidences showed that the model accurately predicted outcomes in the semaglutide arm, and slightly overestimated kidney failure incidence in the placebo arm (Table 1).Table 1Projected versus observed kidney failure cumulative incidenceFull FLOW populationSemaglutide 1 mgPlaceboProjected kidney failure incidence at year 37.1%10.8%Projected kidney failure incidence at year 48.7%13.8%Observed kidney failure incidence at 3.4 years in FLOW8.0%9.3% Table 1Projected versus observed kidney failure cumulative incidenceFull FLOW populationSemaglutide 1 mgPlaceboProjected kidney failure incidence at year 37.1%10.8%Projected kidney failure incidence at year 48.7%13.8%Observed kidney failure incidence at 3.4 years in FLOW8.0%9.3% Projected versus observed kidney failure cumulative incidence Over patient lifetimes, mean life expectancy increased by 0.73 years and quality-adjusted life expectancy improved by 0.60 QALYs with semaglutide compared with placebo (Table 2, Fig. 1). The most notable difference in the incidence of complications between the treatment arms was observed for kidney failure, where treatment with semaglutide reduced the cumulative incidence from 48% to 35% over patient lifetimes compared with placebo (Fig. 2, Fig. 3). Patients receiving semaglutide were projected to experience kidney failure for a mean time period of 1.20 years versus 1.73 years with placebo. Assuming all patients with kidney failure were treated with dialysis and assuming three dialysis sessions per week, the average patient receiving semaglutide required 83 fewer dialysis sessions over their lifetime compared with the average patient receiving placebo. The clinical benefits associated with semaglutide were accompanied by mean cost savings of DKK 6,068 per person over patient lifetimes (Table 2). The higher cost of treatment (DKK 71,263) was fully offset by the cost savings from avoidance of kidney failure (DKK 91,931) with semaglutide compared with placebo (Fig. 4). This was observed despite increased survival with semaglutide. As a result, over the long-term, semaglutide was projected to be a dominant treatment compared with placebo.Fig. 1Survival curve from the full FLOW population analysisFig. 2Cumulative incidence of T2D-related complications over patient lifetimes in the full FLOW population analysisFig. 3Cumulative incidence of kidney failure over time in the full FLOW population analysisFig. 4Direct costs over patient lifetimes in the full FLOW population analysis. DKK, 2023 Danish kronerTable 2Base case analysis resultsSemaglutide 1 mgPlaceboDifferenceFull FLOW populationDiscounted life expectancy, years6.635.90 + 0.73Discounted quality-adjusted life expectancy, QALYs5.194.59 + 0.60Discounted direct costs, DKK818,116824,183 − 6,068ICER, DKK per QALY gainedSemaglutide dominantSubgroup receiving SGLT-2 inhibitors at baselineDiscounted life expectancy, years7.466.97 + 0.49Discounted quality-adjusted life expectancy, QALYs5.815.37 + 0.44Discounted direct costs, DKK854,547846,051 + 8,496ICER, DKK per QALY gained19,167Subgroup not receiving SGLT-2 inhibitors at baselineDiscounted life expectancy, years6.475.71 + 0.77Discounted quality-adjusted life expectancy, QALYs5.074.45 + 0.62Discounted direct costs, DKK809,987819,199 − 9,212ICER, DKK per QALY gainedSemaglutide dominantDKK, 2023 Danish Kroner; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2 Survival curve from the full FLOW population analysis Cumulative incidence of T2D-related complications over patient lifetimes in the full FLOW population analysis Cumulative incidence of kidney failure over time in the full FLOW population analysis Direct costs over patient lifetimes in the full FLOW population analysis. DKK, 2023 Danish kroner Table 2Base case analysis resultsSemaglutide 1 mgPlaceboDifferenceFull FLOW populationDiscounted life expectancy, years6.635.90 + 0.73Discounted quality-adjusted life expectancy, QALYs5.194.59 + 0.60Discounted direct costs, DKK818,116824,183 − 6,068ICER, DKK per QALY gainedSemaglutide dominantSubgroup receiving SGLT-2 inhibitors at baselineDiscounted life expectancy, years7.466.97 + 0.49Discounted quality-adjusted life expectancy, QALYs5.815.37 + 0.44Discounted direct costs, DKK854,547846,051 + 8,496ICER, DKK per QALY gained19,167Subgroup not receiving SGLT-2 inhibitors at baselineDiscounted life expectancy, years6.475.71 + 0.77Discounted quality-adjusted life expectancy, QALYs5.074.45 + 0.62Discounted direct costs, DKK809,987819,199 − 9,212ICER, DKK per QALY gainedSemaglutide dominantDKK, 2023 Danish Kroner; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2 Base case analysis results DKK, 2023 Danish Kroner; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2 Key drivers of clinical outcomes In the base case analysis with all differences in risk factors included, semaglutide was associated with improved quality-adjusted life expectancy of 0.60 QALYs compared with placebo. The key drivers of this improvement were eGFR benefits, with the first-year and subsequent annual changes in eGFR accounting for 19% and 54% of the quality-adjusted life expectancy increase, respectively, and 73% combined (Table 3). Changes in HbA1c and BMI also made notable impacts, contributing 11% and 9% of the quality-adjusted life expectancy difference, respectively. Changes in SBP and serum lipids made smaller contributions to the clinical benefits with semaglutide (3% and 2%, respectively).Table 3Contribution of differences in each risk factor to total quality-adjusted life expectancy gainsDriversQuality-adjusted life expectancy, QALYsContribution, %Semaglutide 1 mgPlaceboDifferenceBase case5.194.590.60100%HbA1c difference only4.654.590.0711%SBP difference only4.614.590.023%BMI difference only4.654.590.069%eGFR benefits difference only5.034.590.4473% eGFR first-year change difference only4.714.590.1219% eGFR progression difference only4.924.590.3354%Serum lipids difference only4.604.590.012%BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; QALYs, quality-adjusted life years; SBP, systolic blood pressure Table 3Contribution of differences in each risk factor to total quality-adjusted life expectancy gainsDriversQuality-adjusted life expectancy, QALYsContribution, %Semaglutide 1 mgPlaceboDifferenceBase case5.194.590.60100%HbA1c difference only4.654.590.0711%SBP difference only4.614.590.023%BMI difference only4.654.590.069%eGFR benefits difference only5.034.590.4473% eGFR first-year change difference only4.714.590.1219% eGFR progression difference only4.924.590.3354%Serum lipids difference only4.604.590.012%BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; QALYs, quality-adjusted life years; SBP, systolic blood pressure Contribution of differences in each risk factor to total quality-adjusted life expectancy gains BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; QALYs, quality-adjusted life years; SBP, systolic blood pressure Sensitivity analyses Results of the sensitivity analyses showed that the outcomes of the long-term analysis based on the full FLOW population and the two subgroups were robust to changes in input parameters and assumptions (Table 4).Table 4Sensitivity analysis results in the full populationAnalysisDiscounted quality-adjusted life expectancy, QALYsDiscounted direct costs, DKKICER, DKK per QALY gainedSemaglutide 1 mgPlaceboDifferenceSemaglutide 1 mgPlaceboDifferenceBase case5.194.59 + 0.60818,116824,183− 6,068Semaglutide 1 mg dominant10-year time horizon4.253.97 + 0.28591,083624,821− 33,738Semaglutide 1 mg dominant20-year time horizon5.114.55 + 0.56791,986807,390− 15,404Semaglutide 1 mg dominant0% discount rates6.145.31 + 0.831,016,0431,007,317 + 8,72610,5582.5% discount rates5.334.69 + 0.63846,078850,399 − 4,321Semaglutide 1 mg dominant3.5% discount rates5.064.49 + 0.57791,803799,401− 7,598Semaglutide 1 mg dominantStatistically significant clinical differences only*5.194.59 + 0.60818,312824,183 − 5,871Semaglutide 1 mg dominantTreatment discontinuation after 3 years, all differences abolished4.754.59+ 0.16825,516824,183+ 1,3338,382Treatment discontinuation after 3 years, parallel eGFR4.954.59+ 0.36796,843824,183 − 27,341Semaglutide 1 mg dominantTreatment discontinuation after 5 years, all differences abolished4.814.59 + 0.22824,108824,183− 75Semaglutide 1 mg dominantTreatment discontinuation after 5 years, parallel eGFR5.074.59 + 0.48810,464824,183 − 13,719Semaglutide 1 mg dominanteGFR progression based on Zoppini et al. (2012)5.595.15 + 0.44775,892772,371+ 3,5218,060Kidney failure cumulative incidence based on UKPDS OM2 risk equation4.924.47 + 0.45838,704837,587+ 1,1172,481BRAVO risk equations applied5.184.60 + 0.58831,242843,937 − 12,694Semaglutide 1 mg dominantRisk of cardiovascular disease increased5.004.42 + 0.58794,989800,789 − 5,800Semaglutide 1 mg dominantCosts of complications + 20%5.194.59 + 0.60946,983968,517 − 21,534Semaglutide 1 mg dominantCosts of complications − 20%5.194.59 + 0.60689,245679,846+ 9,39915,652KDIGO stage 5 cost matched to renal transplant5.194.59 + 0.60727,390685,125+ 42,26570,384No differences in concomitant medication use during trial period5.194.59 + 0.60818,116820,585 − 2,469Semaglutide 1 mg dominantEnd of trial medication use continued for the remainder of patient lifetimes5.194.59 + 0.60782,419794,356 − 11,937Semaglutide 1 mg dominantBMI disutility by Lee et al. (2005)5.054.42 + 0.63818,116824,183 − 6,068Semaglutide 1 mg dominantNo BMI disutility5.414.85 + 0.56818,116824,183 − 6,068Semaglutide 1 mg dominantPSA4.003.55 + 0.44606,842607,343 − 502Semaglutide 1 mg dominantBMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2*The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Table 4Sensitivity analysis results in the full populationAnalysisDiscounted quality-adjusted life expectancy, QALYsDiscounted direct costs, DKKICER, DKK per QALY gainedSemaglutide 1 mgPlaceboDifferenceSemaglutide 1 mgPlaceboDifferenceBase case5.194.59 + 0.60818,116824,183− 6,068Semaglutide 1 mg dominant10-year time horizon4.253.97 + 0.28591,083624,821− 33,738Semaglutide 1 mg dominant20-year time horizon5.114.55 + 0.56791,986807,390− 15,404Semaglutide 1 mg dominant0% discount rates6.145.31 + 0.831,016,0431,007,317 + 8,72610,5582.5% discount rates5.334.69 + 0.63846,078850,399 − 4,321Semaglutide 1 mg dominant3.5% discount rates5.064.49 + 0.57791,803799,401− 7,598Semaglutide 1 mg dominantStatistically significant clinical differences only*5.194.59 + 0.60818,312824,183 − 5,871Semaglutide 1 mg dominantTreatment discontinuation after 3 years, all differences abolished4.754.59+ 0.16825,516824,183+ 1,3338,382Treatment discontinuation after 3 years, parallel eGFR4.954.59+ 0.36796,843824,183 − 27,341Semaglutide 1 mg dominantTreatment discontinuation after 5 years, all differences abolished4.814.59 + 0.22824,108824,183− 75Semaglutide 1 mg dominantTreatment discontinuation after 5 years, parallel eGFR5.074.59 + 0.48810,464824,183 − 13,719Semaglutide 1 mg dominanteGFR progression based on Zoppini et al. (2012)5.595.15 + 0.44775,892772,371+ 3,5218,060Kidney failure cumulative incidence based on UKPDS OM2 risk equation4.924.47 + 0.45838,704837,587+ 1,1172,481BRAVO risk equations applied5.184.60 + 0.58831,242843,937 − 12,694Semaglutide 1 mg dominantRisk of cardiovascular disease increased5.004.42 + 0.58794,989800,789 − 5,800Semaglutide 1 mg dominantCosts of complications + 20%5.194.59 + 0.60946,983968,517 − 21,534Semaglutide 1 mg dominantCosts of complications − 20%5.194.59 + 0.60689,245679,846+ 9,39915,652KDIGO stage 5 cost matched to renal transplant5.194.59 + 0.60727,390685,125+ 42,26570,384No differences in concomitant medication use during trial period5.194.59 + 0.60818,116820,585 − 2,469Semaglutide 1 mg dominantEnd of trial medication use continued for the remainder of patient lifetimes5.194.59 + 0.60782,419794,356 − 11,937Semaglutide 1 mg dominantBMI disutility by Lee et al. (2005)5.054.42 + 0.63818,116824,183 − 6,068Semaglutide 1 mg dominantNo BMI disutility5.414.85 + 0.56818,116824,183 − 6,068Semaglutide 1 mg dominantPSA4.003.55 + 0.44606,842607,343 − 502Semaglutide 1 mg dominantBMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2*The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Sensitivity analysis results in the full population BMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2 *The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Based on the full FLOW population results, semaglutide was predicted to remain a dominant treatment compared with placebo in most analyses. In the remaining analyses, semaglutide was associated with improved clinical outcomes and increased costs, with ICERs remaining below the willingness-to-pay threshold estimated to range of DKK 458,134–969,518 per QALY gained in Denmark [56]. When discount rates of 0% were applied, semaglutide was associated with a larger increase in quality-adjusted life expectancy than in the base case analysis, but also increased incremental costs. This was due to the “survival paradox”, where improved survival in the semaglutide arm resulted in higher costs over the long term, particularly in the extended period of life in later years of the simulation. Without discounting applied, these future costs had a greater impact, leading to higher cumulative costs with semaglutide. When semaglutide was discontinued after 3 years and all differences in risk factors between the treatment arms were abolished, semaglutide was associated with smaller clinical benefits compared with the base case and increased costs, as differences between the treatment arms were maintained for only 3 years. When the eGFR slopes ran parallel following treatment discontinuation and when semaglutide was received for 5 years, semaglutide remained dominant. In the analyses with the Zoppini et al. eGFR progression and UKPDS OM2 renal failure risk equation applied, the incidence of kidney failure was lower in both treatment arms, with a smaller difference between them. The higher costs of treatment associated with semaglutide were, therefore, only partially offset by the cost savings from avoided kidney failure events, and semaglutide was associated with higher direct costs. Additionally, in the UKPDS OM2 risk equation, eGFR is included as a categorical variable based on a threshold of 60 mL/min/1.73 m2 rather than a continuous variable, limiting the model’s ability to accurately capture the differences in eGFR trajectories between treatment arms over time. Decreasing the costs of diabetes-related complications by 20% and applying the cost of renal transplant for patients with kidney failure reduced the costs of treating complications, leading to smaller cost offsets with semaglutide and increased costs overall. The probabilistic analysis found that the probability that semaglutide was considered dominant over placebo was 51.4% (Fig. 5). At a willingness-to-pay threshold of DKK 458,134 per QALY gained, the lower end of the range of thresholds reported for Denmark, there was a 100% probability that semaglutide was considered cost-effective. Fig. 5Cost-effectiveness acceptability curve in the full FLOW population analysis. DKK, 2023 Danish kroner; QALY, quality-adjusted life year Cost-effectiveness acceptability curve in the full FLOW population analysis. DKK, 2023 Danish kroner; QALY, quality-adjusted life year Subgroup analysis The cost-effectiveness analysis performed in patients not receiving SGLT-2 inhibitors at baseline resulted in increased mean life expectancy by 0.77 years and improved quality-adjusted life expectancy by 0.62 QALYs with semaglutide compared with placebo, similar to the outcomes observed in the full FLOW population (Table 2). Clinical benefits were smaller in the subgroup of patients receiving SGLT-2 inhibitors at baseline with increased mean life expectancy by 0.49 years and improved quality-adjusted life expectancy by 0.44 QALYs with semaglutide compared with placebo. Smaller differences in life expectancy and quality-adjusted life expectancy in the latter subgroup were due to smaller differences in the cumulative incidence of kidney failure. In patients not receiving SGLT-2 inhibitors at baseline, semaglutide was associated with cost savings of DKK 9,212 per person, with the higher cost of semaglutide treatment (DKK 70,524) entirely offset by the cost savings from avoiding kidney failure (DKK 98,041). In patients receiving SGLT-2 inhibitors at baseline, semaglutide was associated with a cost increase of DKK 8,496, with higher treatment costs associated with semaglutide (DKK 74,092) only partially offset by the cost savings from avoided kidney failure events (DKK 54,173). The differences in clinical and cost outcomes between subgroups were mainly driven by the difference in the magnitude of eGFR benefits with semaglutide. The difference in the annual change in eGFR between semaglutide and placebo was smaller in the subgroup with SGLT-2 inhibitor use at baseline compared with the subgroup of patients not receiving SGLT-2 inhibitors and the full population, resulting in a smaller difference in the cumulative incidence of kidney failure and therefore lower costs savings from avoided kidney failure events. Based on long-term clinical and cost projections, semaglutide 1 mg was considered a dominant treatment in the subgroup not receiving SGLT-2 inhibitors at baseline, and a highly cost-effective treatment in the subgroup of patients receiving SGLT-2 inhibitors at baseline, with an ICER of DKK 19,167 per QALY gained falling below the willingness-to-pay threshold of DKK 458,134–969,518 per QALY gained in Denmark. Sensitivity analysis results for both subgroups are shown in Tables 5 and 6. Cost-effectiveness acceptability curves for the two subgroups are shown in Figs. 6 and 7.Table 5Sensitivity analysis results in the subgroup receiving SGLT-2 inhibitors at baselineAnalysisDiscounted quality − adjusted life expectancy, QALYsDiscounted direct costs, DKKICER, DKK per QALY gainedSemaglutide 1 mgPlaceboDifferenceSemaglutide 1 mgPlaceboDifferenceBase case5.815.37+ 0.44854,547846,051+ 8,49619,16710 − year time horizon4.614.40+ 0.21571,733581,234 − 9,501Semaglutide 1 mg dominant20 − year time horizon5.705.29+ 0.41816,353815,304+ 1,0502,5560% discount rates6.976.36+ 0.611,088,4671,067,899+ 20,56833,6792.5% discount rates5.985.51+ 0.47887,197877,233+ 9,96421,3733.5% discount rates5.655.23+ 0.42823,954816,763+ 7,19117,045Statistically significant clinical differences only*5.655.34+ 0.31858,937834,876+ 24,06277,523Treatment discontinuation after 3 years, all differences abolished5.495.37+ 0.12840,921846,051 − 5,130Semaglutide 1 mg dominantTreatment discontinuation after 3 years, parallel eGFR5.645.37+ 0.27820,745846,051 − 25,306Semaglutide 1 mg dominantTreatment discontinuation after 5 years, all differences abolished5.545.37+ 0.17852,464846,051+ 6,41436,810Treatment discontinuation after 5 years, parallel eGFR5.685.37+ 0.31833,244846,051 − 12,807Semaglutide 1 mg dominanteGFR progression based on Zoppini et al. (2012)6.365.97+ 0.39791,161777,107+ 14,05336,362ESKD cumulative incidence based on UKPDS OM2 risk equation5.605.23+ 0.38872,804860,887+ 11,91631,748BRAVO risk equations applied5.725.29+ 0.43858,388854,552+ 3,8378,895Risk of cardiovascular disease increased5.635.19+ 0.44833,317822,145+ 11,17225,394Costs of complications + 20%5.815.37+ 0.44986,089990,712 − 4,623Semaglutide 1 mg dominantCosts of complications − 20%5.815.37+ 0.44723,001701,386+ 21,61648,764KDIGO stage 5 cost matched to renal transplant5.815.37+ 0.44759,798720,714+ 39,08488,174No differences in concomitant medication use during trial period5.815.37+ 0.44854,547842,938+ 11,60926,191End of trial medication use continued for the remainder of patient lifetimes5.815.37+ 0.44830,355824,652+ 5,70212,864BMI disutility by Lee et al. (2005)5.675.19+ 0.48854,547846,051+ 8,49617,709No BMI disutility6.045.65+ 0.39854,547846,051+ 8,49622,006PSA4.534.17+ 0.36632,829623,717+ 9,11225,282BMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SGLT-u, sodium-glucose cotransporter-2; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2*The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFRTable 6Sensitivity analysis results in the subgroup not receiving SGLT-2 inhibitors at baselineAnalysisDiscounted quality − adjusted life expectancy, QALYsDiscounted direct costs, DKKICER, DKK per QALY gainedSemaglutide 1 mgPlaceboDifferenceSemaglutide 1 mgPlaceboDifferenceBase case5.074.45+ 0.62809,987819,199 − 9,212Semaglutide 1 mg dominant10 − year time horizon4.193.89+ 0.30593,986631,642 − 37,656Semaglutide 1 mg dominant20 − year time horizon5.004.42+ 0.59786,478804,352 − 17,873Semaglutide 1 mg dominant0% discount rates5.985.13+ 0.851,000,583995,573+ 5,0105,8852.5% discount rates5.214.55+ 0.65836,993844,531 − 7,538Semaglutide 1 mg dominant3.5% discount rates4.954.36+ 0.59784,548795,223 − 10,675Semaglutide 1 mg dominantStatistically significant clinical differences only*5.074.45+ 0.62809,435819,199 − 9,764Semaglutide 1 mg dominantTreatment discontinuation after 3 years, all differences abolished4.614.45+ 0.16817,004819,199 − 2,195Semaglutide 1 mg dominantTreatment discontinuation after 3 years, parallel eGFR4.764.45+ 0.30796,745819,199 − 22,454Semaglutide 1 mg dominantTreatment discontinuation after 5 years, all differences abolished4.684.45+ 0.23815,168819,199 − 4,031Semaglutide 1 mg dominantTreatment discontinuation after 5 years, parallel eGFR4.854.45+ 0.39797,255819,199 − 21,944Semaglutide 1 mg dominanteGFR progression based on Zoppini et al. (2012)5.455.00+ 0.45770,653770,622+ 3170ESKD cumulative incidence based on UKPDS OM2 risk equation4.794.34+ 0.45830,122829,175+ 9472,090BRAVO risk equations applied5.074.47+ 0.61825,522838,254 − 12,732Semaglutide 1 mg dominantRisk of cardiovascular disease increased4.894.28+ 0.61786,082792,683 − 6,601Semaglutide 1 mg dominantCosts of complications + 20%5.074.45+ 0.62938,218963,376 − 25,159Semaglutide 1 mg dominantCosts of complications − 20%5.074.45+ 0.62681,754675,018+ 6,73610,830KDIGO stage 5 cost matched to renal transplant5.074.45+ 0.62720,293678,405+ 41,88867,346No differences in concomitant medication use during trial period5.074.45+ 0.62809,987815,419 − 5,432Semaglutide 1 mg dominantEnd of trial medication use continued for the remainder of patient lifetimes5.074.45+ 0.62771,459787,590 − 16,131Semaglutide 1 mg dominantBMI disutility by Lee et al. (2005)4.944.29+ 0.65809,987819,199 − 9,212Semaglutide 1 mg dominantNo BMI disutility5.294.70+ 0.58809,987819,199 − 9,212Semaglutide 1 mg dominantPSA3.903.45+ 0.45600,862603,668 − 2,807Semaglutide 1 mg dominantBMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2*The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFRFig. 6 Cost-effectiveness acceptability curve in the subgroup receiving SGLT-2 inhibitors at baseline. DKK, 2023 Danish kroner; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2Fig. 7Cost-effectiveness acceptability curve in the subgroup not receiving SGLT-2 inhibitors at baseline. DKK, 2023 Danish kroner; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2 Table 5Sensitivity analysis results in the subgroup receiving SGLT-2 inhibitors at baselineAnalysisDiscounted quality − adjusted life expectancy, QALYsDiscounted direct costs, DKKICER, DKK per QALY gainedSemaglutide 1 mgPlaceboDifferenceSemaglutide 1 mgPlaceboDifferenceBase case5.815.37+ 0.44854,547846,051+ 8,49619,16710 − year time horizon4.614.40+ 0.21571,733581,234 − 9,501Semaglutide 1 mg dominant20 − year time horizon5.705.29+ 0.41816,353815,304+ 1,0502,5560% discount rates6.976.36+ 0.611,088,4671,067,899+ 20,56833,6792.5% discount rates5.985.51+ 0.47887,197877,233+ 9,96421,3733.5% discount rates5.655.23+ 0.42823,954816,763+ 7,19117,045Statistically significant clinical differences only*5.655.34+ 0.31858,937834,876+ 24,06277,523Treatment discontinuation after 3 years, all differences abolished5.495.37+ 0.12840,921846,051 − 5,130Semaglutide 1 mg dominantTreatment discontinuation after 3 years, parallel eGFR5.645.37+ 0.27820,745846,051 − 25,306Semaglutide 1 mg dominantTreatment discontinuation after 5 years, all differences abolished5.545.37+ 0.17852,464846,051+ 6,41436,810Treatment discontinuation after 5 years, parallel eGFR5.685.37+ 0.31833,244846,051 − 12,807Semaglutide 1 mg dominanteGFR progression based on Zoppini et al. (2012)6.365.97+ 0.39791,161777,107+ 14,05336,362ESKD cumulative incidence based on UKPDS OM2 risk equation5.605.23+ 0.38872,804860,887+ 11,91631,748BRAVO risk equations applied5.725.29+ 0.43858,388854,552+ 3,8378,895Risk of cardiovascular disease increased5.635.19+ 0.44833,317822,145+ 11,17225,394Costs of complications + 20%5.815.37+ 0.44986,089990,712 − 4,623Semaglutide 1 mg dominantCosts of complications − 20%5.815.37+ 0.44723,001701,386+ 21,61648,764KDIGO stage 5 cost matched to renal transplant5.815.37+ 0.44759,798720,714+ 39,08488,174No differences in concomitant medication use during trial period5.815.37+ 0.44854,547842,938+ 11,60926,191End of trial medication use continued for the remainder of patient lifetimes5.815.37+ 0.44830,355824,652+ 5,70212,864BMI disutility by Lee et al. (2005)5.675.19+ 0.48854,547846,051+ 8,49617,709No BMI disutility6.045.65+ 0.39854,547846,051+ 8,49622,006PSA4.534.17+ 0.36632,829623,717+ 9,11225,282BMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SGLT-u, sodium-glucose cotransporter-2; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2*The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Sensitivity analysis results in the subgroup receiving SGLT-2 inhibitors at baseline BMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SGLT-u, sodium-glucose cotransporter-2; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2 *The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Table 6Sensitivity analysis results in the subgroup not receiving SGLT-2 inhibitors at baselineAnalysisDiscounted quality − adjusted life expectancy, QALYsDiscounted direct costs, DKKICER, DKK per QALY gainedSemaglutide 1 mgPlaceboDifferenceSemaglutide 1 mgPlaceboDifferenceBase case5.074.45+ 0.62809,987819,199 − 9,212Semaglutide 1 mg dominant10 − year time horizon4.193.89+ 0.30593,986631,642 − 37,656Semaglutide 1 mg dominant20 − year time horizon5.004.42+ 0.59786,478804,352 − 17,873Semaglutide 1 mg dominant0% discount rates5.985.13+ 0.851,000,583995,573+ 5,0105,8852.5% discount rates5.214.55+ 0.65836,993844,531 − 7,538Semaglutide 1 mg dominant3.5% discount rates4.954.36+ 0.59784,548795,223 − 10,675Semaglutide 1 mg dominantStatistically significant clinical differences only*5.074.45+ 0.62809,435819,199 − 9,764Semaglutide 1 mg dominantTreatment discontinuation after 3 years, all differences abolished4.614.45+ 0.16817,004819,199 − 2,195Semaglutide 1 mg dominantTreatment discontinuation after 3 years, parallel eGFR4.764.45+ 0.30796,745819,199 − 22,454Semaglutide 1 mg dominantTreatment discontinuation after 5 years, all differences abolished4.684.45+ 0.23815,168819,199 − 4,031Semaglutide 1 mg dominantTreatment discontinuation after 5 years, parallel eGFR4.854.45+ 0.39797,255819,199 − 21,944Semaglutide 1 mg dominanteGFR progression based on Zoppini et al. (2012)5.455.00+ 0.45770,653770,622+ 3170ESKD cumulative incidence based on UKPDS OM2 risk equation4.794.34+ 0.45830,122829,175+ 9472,090BRAVO risk equations applied5.074.47+ 0.61825,522838,254 − 12,732Semaglutide 1 mg dominantRisk of cardiovascular disease increased4.894.28+ 0.61786,082792,683 − 6,601Semaglutide 1 mg dominantCosts of complications + 20%5.074.45+ 0.62938,218963,376 − 25,159Semaglutide 1 mg dominantCosts of complications − 20%5.074.45+ 0.62681,754675,018+ 6,73610,830KDIGO stage 5 cost matched to renal transplant5.074.45+ 0.62720,293678,405+ 41,88867,346No differences in concomitant medication use during trial period5.074.45+ 0.62809,987815,419 − 5,432Semaglutide 1 mg dominantEnd of trial medication use continued for the remainder of patient lifetimes5.074.45+ 0.62771,459787,590 − 16,131Semaglutide 1 mg dominantBMI disutility by Lee et al. (2005)4.944.29+ 0.65809,987819,199 − 9,212Semaglutide 1 mg dominantNo BMI disutility5.294.70+ 0.58809,987819,199 − 9,212Semaglutide 1 mg dominantPSA3.903.45+ 0.45600,862603,668 − 2,807Semaglutide 1 mg dominantBMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2*The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Sensitivity analysis results in the subgroup not receiving SGLT-2 inhibitors at baseline BMI, body mass index; BRAVO, Building, Relating, Assessing, and Validating Outcomes; DKK, 2023 Danish Kroner; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; KDIGO, Kidney Disease: Improving Global Outcomes; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2; UKPDS OM2, UK Prospective Diabetes Study Outcomes Model 2 *The differences in the following risk factors were statistically significant: Changes in HbA1c, BMI, SBP, HDL, and hemoglobin in year 1, 2, and 3; changes in LDL in year 1, change in eGFR in year 1, annual change in eGFR Cost-effectiveness acceptability curve in the subgroup receiving SGLT-2 inhibitors at baseline. DKK, 2023 Danish kroner; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2 Cost-effectiveness acceptability curve in the subgroup not receiving SGLT-2 inhibitors at baseline. DKK, 2023 Danish kroner; QALY, quality-adjusted life year; SGLT-2, sodium-glucose cotransporter-2 Discussion In the present analysis, treatment with GLP-1 receptor agonist semaglutide 1 mg was projected to improve clinical outcomes and reduce direct costs and was therefore considered a dominant treatment compared with placebo in people with T2D and CKD based on the FLOW randomized controlled trial. The slower decline in eGFR with semaglutide was the key driver of improved clinical outcomes and cost savings, as this resulted in a reduced cumulative incidence of kidney failure compared with placebo. Assessing cost-effectiveness over shorter time horizons aligned with the duration of FLOW supported the conclusions of the long-term analysis, with semaglutide considered a dominant treatment compared with placebo. The comparison between projected and observed kidney failure outcomes at years 3 and 4 and demonstrated that the PRIME T2D Model accurately estimates kidney failure incidence, due to the modeling approach based on eGFR decline. Similar results as in the full FLOW population were obtained in patients not receiving SGLT-2 inhibitors at baseline, with semaglutide projected to be a dominant treatment compared with placebo over the long term. In the subgroup of patients using SGLT-2 inhibitors at baseline, the outcomes differed slightly and semaglutide was projected to be a cost-effective treatment option. In this subgroup, the difference in eGFR annual change between treatment arms was smaller, leading to a smaller difference in kidney failure incidence, and therefore lower cost savings from preventing kidney failure events with semaglutide versus placebo. The ICER of DKK 19,167 per QALY gained was far below the estimated willingness-to-pay threshold in Denmark (DKK 458,134–969,518 per QALY gained) and semaglutide remained a highly cost-effective treatment compared with placebo. This result should be taken in context, as the data used to inform this analysis is based on a relatively small number of participants in FLOW. The subgroup analyses conducted captured patients on SGLT-2 inhibitors at baseline, but initiation of SGLT-2 inhibitors during the trial was also permitted. In FLOW, 15.6% of participants used SGLT-2 inhibitors at baseline, and by the end of the trial 35% of participants were using SGLT-2 inhibitors. More patients in the placebo arm initiated an SGLT-2 inhibitor than in the semaglutide arm (20% versus 10%). Among participants who either reported SGLT-2 inhibitors use at baseline or initiated an SGLT-2 inhibitor during the study, 14.6% and 16.6% experienced the primary outcome with semaglutide and placebo, respectively (HR 0.88, 95% CI 0.66–1.17). In patients who did not receive SGLT-2 inhibitors at baseline or during the study, 20.7% experienced the primary outcome with semaglutide and 27.2% experienced the primary outcome with placebo (HR 0.70, 95% CI 0.59–0.82) [24]. The inclusion of SGLT-2 inhibitors as part of SoC likely reduced differences between treatment arms. The present analysis can be considered conservative, as greater differences between the trial arms would be expected if initiation of SGLT-2 inhibitors had been prohibited in the study protocol. This is confirmed by the post-hoc analysis where semaglutide reduced the risk of the primary outcome by 30% in patients who did not use SGLT-2 inhibitors during the trial compared with 27% in the full FLOW population [24]. The present analysis remains valid despite SGLT-2 inhibitors now being part of SoC. While the FLOW trial does not allow a direct comparison of the cost-effectiveness of semaglutide 1 mg with SGLT-2 inhibitors, this should form a focus for future clinical trials and subsequent cost-effectiveness analyses. However, the stratification of patients by SGLT-2 inhibitor use allowed assessment of the cost-effectiveness of semaglutide as an add-on to this therapy class. One of the strengths of the present study was the robust clinical trial evidence on which it was based. The data were gathered over a relatively long trial duration (median follow up of 3.4 years), allowing accurate modeling of risk factors over the first 3 years of the analysis. In addition, the FLOW clinical trial reported a high granularity of data, and this enabled accurate modeling of both risk factors and resource use. However, the applicability of the FLOW trial to the Danish setting needs to be considered, as it impacts how likely it is that the efficacy data from the trial will be reflected in real-world effectiveness. A real-world study of people with CKD (with and without T2D) in Denmark found that of 1,029 individuals, the percentages of patients in KDIGO stages 1, 2, 3a, 3b, 4 and 5 were 10%, 25%, 42%, 18%, 5% and 0.2%, respectively [7]. Of the 481 people with diabetes, the mean age was 75 years (standard deviation 10 years). In the FLOW trial, the percentages of patients in KDIGO stages 1, 2, 3a, 3b, 4 and 5 were 1%, 20%, 30%, 38% and 11%, respectively, while mean age was 66.6 years (standard deviation 9.00 years). Differences between these patient characteristics are likely to be due to the inclusion criteria of the FLOW trial, as described in previous publications [22]. In addition, the FLOW trial enrolled patients with a variety of ethnicities, while the Danish population is predominantly Caucasian. As semaglutide becomes more widely used to treat people with T2D and CKD in Denmark, data should be collected to ensure that the outcomes observed in the FLOW trial are also observed in real-world clinical practice. Treatment of CKD is undergoing rapid change, with new Danish CKD guidelines published in 2024 [14]. The FLOW trial was conducted over a long period, meaning that care has evolved since the trial was started. The use of SGLT-2 inhibitors has become SoC in people with CKD and T2D in Denmark (as recommended by the Danish Endocrinology Society [DES]), due to the associated kidney-protective effects, but use was relatively low during the FLOW trial [14, 15, 57]. In addition, SoC in FLOW did include MRA treatment, but not the newer, more effective, ns-MRA therapies (e.g., finerenone), which have now been included in the treatment guidelines for CKD by the American Diabetes Association (ADA), KDIGO, the European Renal Association (ERA) and the Danish Nephrology Society (DNS) [12, 13, 58, 59]. Ns-MRA use was not captured in the present analysis, neither in the clinical nor cost inputs. The inclusion of ns-MRA in future clinical and cost-effectiveness research to evaluate the impact of the use of semaglutide alongside finerenone should be a priority. As well as changes to SoC, changes to cost-effectiveness will occur as GLP-1 receptor agonists and SGLT-2 inhibitors come off patent in the future. The GLP-1 receptor agonist liraglutide came off patent in 2024, and other GLP-1 receptor agonists and SGLT-2 inhibitors will follow in the coming 1–14 years, with the semaglutide patent expiring between 2026–2032 and patents for SGLT-2 inhibitors dapagliflozin and empagliflozin beginning to expire in 2028 [60, 61]. As a result, it is likely that lower price GLP-1 receptor agonists and SGLT-2 inhibitors will become available in the future. However, the degree to which prices will fall and the potential supply of lower cost formulations is unknown, and therefore this could not be reflected in the current analysis. While the impact of patent expiry could not be quantitively captured in the analysis, any fall in the price of semaglutide associated with patent expiry would result to improved long-term cost-effectiveness outcomes. Discontinuation and adherence to treatments were not modeled in the base case analyses. The percentage of patients discontinuing treatment permanently in FLOW was similar across the treatment arms (27.8% in the semaglutide arm and 29.7% in the placebo arm). The base case analysis took a conservative approach as the cost of semaglutide was accrued for the duration of patient lifetimes, and the impact of discontinuation was assessed in sensitivity analyses in which patients discontinued semaglutide therapy after 3 and 5 years. Capturing discontinuation and adherence in a robust manner is challenging, as both costs and clinical outcomes are impacted, but the degree to which each of these are affected is unclear. Additionally, patients in the FLOW trial received a variety of medications, and the effects of non-adherence vary for each treatment and combination of treatments. Therefore, appropriate assumptions to capture discontinuation and adherence are challenging to define. The analysis also did not capture the rare but potentially serious adverse events associated with GLP-1 receptor agonists. A previously published meta-analysis has suggested that GLP-1 receptor agonists are associated with an increased risk of gall bladder disease [62]. However, in the FLOW clinical trial, the incidence of gall bladder disorders was similar in the two trial arms, at 2.26% and 2.83% with semaglutide and placebo, respectively. Additionally, early data suggested that GLP-1 receptor agonists were associated with an increased risk of pancreatitis, but more modern meta-analyses have refuted this association [63]. The incidence of pancreatitis was similar in both arms of FLOW, at 0.68% with semaglutide and 0.51% with placebo. Inclusion of additional adverse events in the cost-effectiveness analysis would be unlikely to change the conclusions of the study. The present analysis is specific to the Danish setting. All cost-effectiveness analyses are country-specific, and results should be interpreted in this context. Pharmacy and complications costs, background mortality and discount rates were specific to Denmark, but clinical inputs were country-agnostic and directly sourced from the FLOW trial. Similar projected clinical outcomes and cost-effectiveness analysis results can be expected in other countries, with some variations due to differences in treatment practices, background mortality rates, and costs. The characteristics of the Danish healthcare environment include universal access to a comprehensive package of health services free of charge, and the results may differ in countries with different healthcare-funding models. Additionally, pharmacy costs are publicly available in Denmark (with no confidential rebates or patient access schemes applied), allowing the analysis to accurately reflect Danish costs, which may not be possible for cost-effectiveness analyses conducted for other country settings. Long-term analyses are inherently associated with uncertainty, as assumptions need to be made to extrapolate data beyond the trial duration. Assumptions used in the base case analysis were based on observations from other long-term studies and were tested in sensitivity analyses. Across these, the conclusions of the analysis were found to remain unchanged from those of the base case analysis. The FLOW trial reported differences in hard endpoints with semaglutide versus placebo that could be directly incorporated into a health economic analysis, such as eGFR < 15 mL/min/1.73 m2 (hazard ratio 0.80, 95% confidence interval 0.61 to 1.06), initiation of kidney replacement therapy (hazard ratio 0.84, 95% confidence interval 0.63 to 1.12), non-fatal myocardial infarction (hazard ratio 0.80, 95% confidence interval 0.55 to 1.15), non-fatal stroke (hazard ratio 1.22, 95% confidence interval 0.84 to 1.77), and death from any cause (hazard ratio 0.80, 95% confidence interval 0.67 to 0.95). In addition, the SUSTAIN 6 CVOT previously demonstrated the cardioprotective effects of semaglutide 1 mg. In the present analysis, these differences in complication rates were not directly modeled, but the benefits of treatment with semaglutide were captured through changes in risk factors. The PRIME T2D Model has demonstrated robust results after validation against CVOTs with no calibration required, supporting that the present approach is valid. In addition, a sensitivity analysis accounting for higher cardiovascular risk in people with CKD was performed, with results supporting those observed in the base case. Conclusions Semaglutide 1 mg as an add-on to SoC was projected to improve quality-adjusted life expectancy and reduce costs versus placebo plus SoC from a Danish healthcare perspective, based on data from the full FLOW population. This suggests that it may be a dominant option for people with T2D and CKD in Denmark. Reduced incidence and delayed onset of kidney failure with semaglutide was a key contributor to improved clinical outcomes and cost savings. The analysis in patients not receiving SGLT-2 inhibitors at baseline led to the same conclusion as in the full FLOW population. In the subgroup of patients already receiving SGLT-2 inhibitors at baseline, semaglutide was projected to be cost-effective with an ICER of DKK 19,167 per QALY gained, well below the willingness-to-pay threshold of DKK 458,134–969,518 per QALY gained in Denmark. Healthcare payers and prescribing physicians should consider these findings when evaluating semaglutide 1 mg as a potential treatment option for people with T2D and CKD. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1